Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Orchid Pharma Gains 6%; BSE HEALTHCARE Index Down 0.4%
Tue, 26 Nov 10:34

Orchid Pharma Gains 6%; BSE HEALTHCARE Index Down 0.4%Image source: phive2015/www.istockphoto.com

Orchid Pharma share price has zoomed 6% and is presently trading at Rs 1,600.0.

Meanwhile, the BSE HEALTHCARE index is at 43,216.3 (down 0.4%).

Among the top gainers in the BSE HEALTHCARE index today are MAX HEALTHCARE INSTITUTE (up 2.9%) and CAPLIN POINT (up 2.5%).

POLY MEDICURE (down 7.4%) and IPCA Labs (down 2.2%) are among the top losers today.

Over the last one year, Orchid Pharma has moved up from Rs 588.8 to Rs 1,600.0, registering a gain of Rs 1,011.3 (up 171.8%).

On the other hand, the BSE HEALTHCARE index has moved up from 29,918.9 to 43,216.3, registering a gain of 44.4% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 164.5%), SUVEN PHARMACEUTICALS (up 110.6%) and Glenmark Pharma (up 93.3%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 80,012.8 (down 0.1%).

The top losers among the BSE Sensex today are Ultratech Cement (down 2.3%) and MUNDRA PORT & SEZ (down 2.1%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.

In the meantime, NSE Nifty is at 24,201.3 (down 0.1%). Ultratech Cement and Adani Enterprises are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 66,023.2 to 80,012.8, registering a gain of 13,989.5 points (up 21.2%).

Orchid Pharma Financial Update...

Orchid Pharma net profit grew 29.3% YoY to Rs 259 million for the quarter ended September 2024, compared to a profit of Rs 200 million a year ago. Net sales rose 12.0% to Rs 2,227 million during the period as against Rs 1,988 million in July-September 2023.

For the year ended March 2024, Orchid Pharma reported 72.1% increase in net profit to Rs 951 million compared to net profit of Rs 552 million during FY23. Revenue of the company grew 23.0% to Rs 8,194 million during FY24.

The current Price to earnings ratio of Orchid Pharma, based on rolling 12 month earnings, stands at 68.8.


Equitymaster requests your view! Post a comment on "Orchid Pharma Gains 6%; BSE HEALTHCARE Index Down 0.4%". Click here!